Homocysteine in Pregnancy

Advances in Clinical Chemistry

Volumn 53, Issue C, 2011, Pages 105-137

  Murphy, Michelle M ^a,b   Fernandez Ballart, Joan D ^a,b  

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650988404     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385855-9.00005-9     Document Type: Chapter

References (155)

1. Cantoni G.L., Scarano E. The formation of S-adenosylhomocysteine in enzymatic transmethylation reactions. J. Am. Chem. Soc. 1954, 76:4744.
2. Liveson J. Metabolic diagram. Homocysteine in Health and Disease 2001, ix. Cambridge University Press, Cambridge, UK. R. Carmel, D. Jacobsen (Eds.).
3. MacCoss M.J., Fukagawa N.K., Matthews D.E. Measurement of intracellular sulfur amino acid metabolism in humans. Am. J. Physiol. Endocrinol. Metab. 2001, 280:E947-E955.
4. Leclerc D., Wilson A., Dumas R., et al. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocysteinuria. Proc. Natl. Acad. Sci. USA 1998, 95:3059-3064.
5. Selhub J., Jacques P.F., Wilson P.W., Rush D., Rosenberg I.H. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993, 270:2693-2698.
6. Quinlivan E.P., McPartlin J., McNulty H., et al. Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. Lancet 2002, 359:227-228.
7. Chiuve S.E., Giovannucci E.L., Hankinson S.E., et al. The association between betaine and choline intakes and the plasma concentrations of homocysteine in women. Am. J. Clin. Nutr. 2007, 86:1073-1081.
8. Lee J.E., Jacques P.F., Dougherty L., et al. Are dietary choline and betaine intakes determinants of total homocysteine concentration?. Am. J. Clin. Nutr. 2010, 91:1303-1310.
9. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 1995, 10:111-113.
10. Wilcken B., Bamforth F., Li Z., et al. Geographical and ethnic variation of the 677C>T allele of 5,10-methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J. Med. Genet. 2003, 40:619-625.
11. Guenther B.D., Sheppard C.A., Tran P., Rozen R., Matthews R.G., Ludwig M.L. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nat. Struct. Biol. 1999, 6:359-365.
12. Jacques P.F., Bostom A.G., Williams R.R., et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996, 93:7-9.
13. Chan J., Liyuan D., Mikael L.G., et al. Low dietary choline and low dietary riboflavin during pregnancy influence reproductive outcomes and heart development in mice. Am. J. Clin. Nutr. 2010, 91:1035-1043.
14. Hustad S., Ueland P.M., Vollset S.E., Zhang Y., Bjørke-Monsen A.L., Schneede J. Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin. Chem. 2000, 46:1065-1071.
15. Jacques P.F., Kalmbach R., Bagley P.J., et al. The relationship between riboflavin and plasma total homocysteine in the Framingham Offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. J. Nutr. 2002, 132:283-288.
16. Caudill M.A., Dellschaft N., Solis C., et al. Choline intake, plasma riboflavin, and the phosphatidylethanolamine N-methyltransferase G5465A genotype predict plasma homocysteine in folate-deplete Mexican-American men with the methylenetetrahydrofolate reductase 677TT genotype. J. Nutr. 2009, 139:727-733.
17. McNulty H., McKinley M.C., Wilson B., et al. Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent on riboflavin status: implications for riboflavin requirements. Am. J. Clin. Nutr. 2002, 76:436-441.
18. McNulty H., Dowey le R.C., Strain J.J., et al. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C->T polymorphism. Circulation 2006, 113:74-80.
19. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991, 338:131-137. MRC Vitamin Research Group.
20. Czeizel A.E., Dudás I. Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. N. Engl. J. Med. 1992, 327:1832-1835.
21. Berry R.J., Li Z., Erickson J.D., et al. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N. Engl. J. Med. 1999, 341:1485-1490.
22. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Fed. Regist. 1996, 61:8781-8797. US Food and Drug Administration.
23. Pfeiffer C.M., Caudill S.P., Gunter E.W., Osterloh J., Sampson E.J. Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999-2000. Am. J. Clin. Nutr. 2005, 82:442-450.
24. Mills J.L., Signore C. Neural tube defect rates before and after food fortification with folic acid. Birth Defects Res. A Clin. Mol. Teratol. 2004, 70:844-845.
25. Mills J.L., McPartlin J.M., Kirke P.N., Lee Y.L., Conley M.R., Weir D.G. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995, 345:149-151.
26. Cotter A.M., Molloy A.M., Scott J.M., Daly S.F. Elevated plasma homocysteine in early pregnancy: a risk factor for the development of severe pre-eclampsia. Am. J. Obstet. Gynecol. 2001, 185:781-785.
27. Cotter A.M., Molloy A.M., Scott J.M., Daly S.F. Elevated plasma homocysteine in early pregnancy: a risk factor for the development of nonsevere pre-eclampsia. Am. J. Obstet. Gynecol. 2003, 189:391-394.
28. Onalan R., Onalan G., Gunenc Z., Karabulut E. Combining 2nd-trimester maternal serum homocysteine levels and uterine artery Doppler for prediction of preeclampsia and isolated intrauterine growth restriction. Gynecol. Obstet. Invest. 2006, 61:142-148.
29. Ronnenberg A.G., Goldman M.B., Chen D., et al. Preconception homocysteine and B vitamin status and birth outcomes in Chinese women. Am. J. Clin. Nutr. 2002, 76:1385-1391.
30. Steegers-Theunissen R.P.M., Boers G.H., Blom H.J., et al. Neural tube defects and elevated homocysteine levels in amniotic fluid. Am. J. Obstet. Gynecol. 1995, 172:1436-1441.
31. Wenstrom K.D., Johanning G.L., Johnston K.E., DuBard M. Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations. Am. J. Obstet. Gynecol. 2001, 184:806-812.
32. Barak A.J., Kemmy R.J. Methotrexate effects on hepatic betaine levels in choline-supplemented and choline-deficient rats. Drug Nutr. Interact. 1982, 1:275-278.
33. Fisher M.C., Zeisel S.H., Mar M.-H., Sadler T.W. Inhibitors of choline uptake and metabolism cause developmental abnormalities in neurulating mouse embryos. Teratology 2001, 64:114-122.
34. Shaw G.M., Carmichael S.L., Yang W., Selvin S., Schaffer D.M. Periconceptional dietary intake of choline and betaine and neural tube defects in offspring. Am. J. Epidemiol. 2004, 160:102-109.
35. Shaw G.M., Vollset S.E., Carmichael S.L., et al. Nested case control study of one carbon metabolites in mid-pregnancy and risk of cleft lip with and without cleft lip palate. Pediatr. Res. 2009, 66:501-506.
36. Drouva A.V., Laplante E., Leblanc P., Bechet J., Clauser H., Kordon C. Estradiol activates methylating enzyme(s) involved in the conversion of phosphatidylyethanolamine to phosphatidylcholine in rat pituitary membranes. Endocrinology 1986, 119:2611-2622.
37. Postle A.D., Al M.D.M., Burdge G.C., Hornstra G. The composition of individual molecular species of plasma phosphatidylcholine in human pregnancy. Early Hum. Dev. 1995, 43:47-58.
38. Ozarda IIcol Y., Uncu G., Ulus I.H. Free and phospholipid-bound choline concentrations in serum during pregnancy, after delivery and in newborns. Arch. Physiol. Biochem. 2002, 110:393-399.
39. Velzing-Aarts F.V., Holm P.I., Fokkema M.R., van der Dijs F.P., Ueland P.M., Muskiet F.A. Plasma choline and betaine and their relation to plasma homocysteine in normal pregnancy. Am. J. Clin. Nutr. 2005, 81:1383-1389.
40. Jacques P.F., Rosenberg I.H., Rogers G., et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. Am. J. Clin. Nutr. 1999, 69:482-489.
41. Morris M.S., Jacques P.F., Selhub J., Rosenberg I.H. Total homocysteine and estrogen status indicators in the Third National Health and Nutrition Examination Survey. Am. J. Epidemiol. 2000, 152:140-148.
42. Refsum H., Nurk E., Smith A.D., et al. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J. Nutr. 2006, 136:1731S-1740S.
43. Brattström L., Lindgren A., Israelsson B., Andersson A., Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J. Intern. Med. 1994, 236:633-641.
44. Jacques P.F., Bostom A.G., Wilson P.W., Rich S., Rosenberg I.H., Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am. J. Clin. Nutr. 2001, 73:613-621.
45. Dankner R., Chetrit A., Ken Dror G., Sela B.A. Physical activity is inversely associated with total homocysteine levels, independent of C677T MTHFR genotype and plasma B vitamins. Age 2007, 29:219-227.
46. Björck J., Hellgren M., Råstam L., Lindblad U. Associations between serum insulin and homocysteine in a Swedish population-a potential link between the metabolic syndrome and hyperhomocysteinemia: the Skaraborg project. Metabolism 2006, 55:1007-1013.
47. Mora S., Lee I.M., Buring J.E., Ridker P.M. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA 2006, 295:1412-1419.
48. Kim M.H., Kim E., Passen E.L., Meyer J., Kang S.S. Cortisol and estradiol: nongenetic factors for hyperhomocyst(e)inemia. Metabolism 1997, 46:247-249.
49. Giri S., Thompson P.D., Taxel P., Contois J.H., Otvos J., Allen R., Ens G., Wu A.H.B., Waters D.D. Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. Atherosclerosis 1998, 137:359-366.
50. Madsen J.S., Kristensen S.R., Klitgaard N.A., et al. Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: a randomized controlled study. Am. J. Obstet. Gynecol. 2002, 187:33-39.
51. Tallova J., Tomandl J., Bicikova M., Hill M. Changes of plasma total homocysteine levels during the menstrual cycle. Eur. J. Clin. Invest. 1999, 29:1041-1044.
52. Elhadd T.A., Neary R., Abdu T.A., et al. Influence of the hormonal changes during the normal menstrual cycle in healthy young women on soluble adhesion molecules, plasma homocysteine, free radical markers and lipoprotein fractions. Int. Angiol. 2003, 22:222-228.
53. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274:1049-1057.
54. Ueland P.M., Refsum H., Stabler S.P., Malinow M.R., Andersson A., Allen R.H. Total homocysteine in plasma or serum: methods and clinical applications. Clin. Chem. 1993, 39:1764-1779.
55. Kang S.S., Wong P.W., Malinow M.R. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu. Rev. Nutr. 1992, 12:279-298.
56. Bønaa K.H., Njølstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med. 2006, 354:1578-1588.
57. Ebbing M., Bleie Ø., Ueland P.M., et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008, 300:795-804.
58. Albert C.M., Cook N.R., Gaziano J.M., et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008, 299:2027-2036.
59. Gindler J., Li Z., Berry R.J., et al. Folic acid supplements during pregnancy and risk of miscarriage. Lancet 2001, 358:796-800.
60. Molloy A.M., Kirke P.N., Troendle J.F., et al. Maternal vitamin B12 status and risk of neural tube defects in a population with high neural tube defect prevalence and no folic acid fortification. Pediatrics 2009, 123:917-923.
61. Bodnar L.M., Tang G., Ness R.B., Harger G., Roberts J.M. Periconceptional multivitamin use reduces the risk of preeclampsia. Am. J. Epidemiol. 2006, 164:470-477.
62. Wen S.W., Chen X.K., Rodger M., et al. Folic acid supplementation in early second trimester and the risk of preeclampsia. Am. J. Obstet. Gynecol. 2008, 198:45.e1-45.e7.
63. Murphy M.M., Scott J.M., McPartlin J.M., Fernandez-Ballart J.D. The pregnancy-related decrease in fasting plasma homocysteine is not explained by folic acid supplementation, hemodilution, or a decrease in albumin in a longitudinal study. Am. J. Clin. Nutr. 2002, 76:614-619.
64. Powers R.W., Majors A.K., Kerchner L.J., Conrad K.P. Renal handling of homocysteine during normal pregnancy and preeclampsia. J. Soc. Gynecol. Invest. 2004, 11:45-50.
65. Murphy M.M., Scott J.M., Fernandez-Ballart J.D. Pregnancy-related decrease in total plasma homocysteine. Am. J. Clin. Nutr. 2003, 77:993-994. Reply to L. Brattström.
66. Boxmeer J.C., Steegers-Theunissen R.P., Lindemans J., et al. Homocysteine metabolism in the pre-ovulatory follicle during ovarian stimulation. Hum. Reprod. 2008, 23:2570-2576.
67. Murphy M.M., Scott J.M., Molloy A.M., Arija V., Fernandez-Ballart J.D. Association between estradiol and homocysteine fluctuations during pregnancy. J. Inherit. Metab. Dis. 2003, 26(Suppl.):34.
68. Murphy M.M., Scott J.M., Arija V., Molloy A.M., Fernandez-Ballart J.D. Maternal homocysteine before conception and throughout pregnancy predicts fetal homocysteine and birth weight. Clin. Chem. 2004, 50:1406-1412.
69. Holmes V.A., Wallace J.M., Alexander H.D., et al. Homocysteine is lower in the third trimester of pregnancy in women with enhanced folate status from continued folic acid supplementation. Clin. Chem. 2005, 51:629-634.
70. Dasarathy J., Gruca L.L., Bennett C., et al. Methionine metabolism in human pregnancy. Am. J. Clin. Nutr. 2010, 91:357-365.
71. Monsen A.L., Schneede J., Ueland P.M. Mid-trimester amniotic fluid methionine concentrations: a predictor of birth weight and length. Metabolism 2006, 55:1186-1191.
72. Ayar A., Celik H., Ozcelik O., Kelestimur H. Homocysteine-induced enhancement of spontaneous contractions of myometrium isolated from pregnant women. Acta Obstet. Gynecol. Scand. 2003, 82:789-793.
73. Chen Z., Karaplis A.C., Ackerman S.L., et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum. Mol. Genet. 2001, 10:433-443.
74. Burgoon J.M., Selhub J., Nadeau M., Sadler T.W. Investigation of the effects of folate deficiency on embryonic development through the establishment of a folate deficient mouse model. Teratology 2002, 65:219-227.
75. Li D., Pickell L., Liu Y., Wu Q., Cohn J.S., Rozen R. Maternal methylenetetrahydrofolate reductase deficiency and low dietary folate lead to adverse reproductive outcomes and congenital heart defects in mice. Am. J. Clin. Nutr. 2005, 82:188-195.
76. Pickell L., Li D., Brown K., et al. Methylenetetrahydrofolate reductase deficiency and low dietary folate increase embryonic delay and placental abnormalities in mice. Birth Defects Res. A 2009, 85:531-541.
77. Jakubowski H., Fersht A. Alternative pathways for editing non-cognate amino acids by aminoacyl-tRNA synthetases. Nucleic Acids Res. 1981, 9:3105-3117.
78. Jakubowski H., Goldman E. Synthesis of homocysteine thiolactone by methionyl-tRNA synthetase in cultured mammalian cells. FEBS Lett. 1993, 317:237-240.
79. Jakubowski H., Zhang L., Bardeguez A., Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells. Implications for atherosclerosis. Circ. Res. 2000, 87:45-51.
80. Jakubowski H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J. Nutr. 2000, 130:377S-381S.
81. Chwatko G., Jakubowski H. The determination of homocysteine-thiolactone in human plasma. Anal. Biochem. 2005, 337:271-277.
82. Rosenquist T.H., Ratashak S.A., Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc. Natl. Acad. Sci. USA 1996, 93:15227-15232.
83. Greene N.D.E., Dunlevy L.P.E., Copp A.J. Homocysteine is embryotoxic but does not cause neural tube defects in mouse embryos. Anat. Embryol. 2003, 206:185-191.
84. Hansen D.K., Grafton T.F., Melnyk S., James S.J. Lack of embryo toxicity of homocysteine thiolactone in mouse embryos in vitro. Reprod. Toxicol. 2001, 15:239-244.
85. Kamudhamas A., Pang L., Smith S.D., Sadovsky Y., Nelson D.M. Homocysteine thiolactone induces apoptosis in cultured human trophoblasts: a mechanism for homocysteine-mediated placental dysfunction?. Am. J. Obstet. Gynecol. 2004, 191:563-571.
86. Koz S.T., Gouwy N.T., Demir N., Nedzvetsky V.S., Etem E., Baydas G. Effects of maternal hyperhomocysteinemia induced by methionine intake in oxidative stress and apoptosis in pup rat brain. Int. J. Dev. Neurosci. 2010, 28:325-329.
87. Blaise S.A., Nédélec E., Schroeder H., et al. Gestational vitamin B deficiency leads to homocysteine-associated brain apoptosis and alters neurobehavioral development in rats. Am. J. Pathol. 2007, 170:667-679.
88. Makhro A.V., Mashkina A.P., Solenaya O.A., et al. Prenatal hyperhomocysteinemia as a model of oxidative stress of the brain. Bull. Exp. Biol. Med. 2008, 146:33-35.
89. Bossenmeyer-Pourié C., Blaise S., Pourié G., et al. Methyl donor deficiency affects fetal programming of gastric ghrelin cell organization and function in the rat. Am. J. Pathol. 2010, 176:270-277.
90. Azizi Z.A., Zamani A., Omrani L.R., et al. Effects of hyperhomocysteinemia during the gestational period on ossification in rat embryo. Bone 2010, 46:1344-1348.
91. Ronnenberg A.G., Venners S.A., Xu X., et al. Preconception B-vitamin and homocysteine status, conception, and early pregnancy loss. Am. J. Epidemiol. 2007, 166:304-312.
92. Murphy M.M., Molloy A.M., Ueland P.M., et al. Longitudinal study of the effect of pregnancy on maternal and fetal cobalamin status in healthy women and their offspring. J. Nutr. 2007, 137:1863-1867.
93. Brown A.S., Bottiglieri T., Schaefer C.A., et al. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch. Gen. Psychiatry 2007, 64:31-39.
94. Ebisch I.M., Peters W.H., Thomas C.M., Wetzels A.M., Peer P.G., Steegers-Theunissen R.P. Homocysteine, glutathione and related thiols affect fertility parameters in the (sub)fertile couple. Hum. Reprod. 2006, 21:1725-1733.
95. Pacchiarotti A., Mohamed M.A., Micara G., et al. The possible role of hyperhomocysteinemia on IVF outcome. J. Assist. Reprod. Genet. 2007, 24:459-462.
96. Boxmeer J.C., Macklon N.S., Lindemans J., et al. IVF outcomes are associated with biomarkers of the homocysteine pathway in monofollicular fluid. Hum. Reprod. 2009, 24:1059-1066.
97. Berrocal-Zaragoza M.I., Fernandez-Ballart J.D., Murphy M.M., Cavallé-Busquets P., Sequeira J.M., Quadros E.V. Association between blocking folate receptor autoantibodies and subfertility. Fertil. Steril. 2009, 91:1518-1521.
98. Nelen W.L., Bulten J., Steegers E.A., Blom H.J., Hanselaar A.G., Eskes T.K. Maternal homocysteine and chorionic vascularization in recurrent early pregnancy loss. Hum. Reprod. 2000, 15:954-960.
99. George L., Mills J.L., Johansson A.L.V., et al. Plasma folate levels and risk of spontaneous abortion. JAMA 2002, 288:1867-1873.
100. Gris J.C., Perneger T.V., Quéré I., et al. Antiphospholipid/antiprotien antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study. Blood 2003, 102:3504-3513.
101. Hübner U., Alwan A., Jouma M., Tabbaa M., Schorr H., Herrmann W. Low serum vitamin B12 is associated with recurrent pregnancy loss in Syrian women. Clin. Chem. Lab. Med. 2008, 46:1265-1269.
102. Dodds L., Fell D.B., Dooley K.C., et al. Effect of homocysteine concentration in early pregnancy on gestational hypertensive disorders and other pregnancy outcomes. Clin. Chem. 2008, 54:326-334.
103. Govindaiah V., Naushad S.M., Prabhakara K., et al. Association of parental hyperhomocysteinemia and C677T Methylene tetrahydrofolate reductase (MTHFR) polymorphism with recurrent pregnancy loss. Clin. Biochem. 2009, 42:380-386.
104. Jaslow C.R., Carney J.L., Kutteh W.H. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil. Steril. 2010, 93:1234-1243.
105. Steegers-Theunissen R.P.M., Boers G.H.J., Trijbels F.J., et al. Maternal hyperhomocysteinemia: a risk factor for neural-tube defects?. Metabolism 1994, 43:1475-1480.
106. Van der Put N.M.J., Thomas C.M.G., Eskes T.K.A.B., et al. Altered folate and vitamin B12 metabolism in families with spina bifida offspring. Q. J. Med. 1997, 90:505-510.
107. Lucock M.D., Wild J., Lumb C.H., et al. Risk of neural tube defect-affected pregnancy is associated with a block in maternal one-carbon metabolism at the level of N-5-methyltetrahydrofolate: homocysteine methyltransferase. Biochem. Mol. Med. 1997, 61:28-40.
108. Wenstrom K.D., Johanning G.L., Owen J., et al. Amniotic fluid homocysteine levels, 5,10-methylenetetrahydrafolate reductase genotypes, and neural tube closure sites. Am. J. Med. Genet. 2000, 90:6-11.
109. Candito M., Rivet R., Herbeth B., et al. Nutritional and genetic determinants of vitamin B and homocysteine metabolisms in neural tube defects: a multicenter case-control study. Am. J. Med. Genet. A 2008, 146A:1128-1133.
110. Grandone E., Corrao A.M., Colaizzo D., et al. Homocysteine metabolism in families from southern Italy with neural tube defects: role of genetic and nutritional determinants. Prenat. Diagn. 2006, 26:1-5.
111. Kapusta L., Haagmans M.L.M., Steegers E.A.P., Cuypers M.H.M., Blom H.J., Eskes T.K.A.B. Congenital heart defects and maternal derangement of homocysteine metabolism. J. Pediatr. 1999, 135:773-774.
112. Hobbs C.A., Cleves M.A., Lemynk S., Zhao W., James S.J. Congenital heart defects and abnormal maternal biomarkers of methionine and homocysteine metabolism. Am. J. Clin. Nutr. 2005, 81:147-153.
113. Hobbs C.A., James S.J., Jernigan S., Melnyk S., Lu Y., Malik S., Cleves M.A. Congenital heart defects, maternal homocysteine, smoking, and the 677 C>T polymorphism in the methylenetetrahydrofolate reductase gene: evaluating gene-environment interactions. Am. J. Obstet. Gynecol. 2006, 194:218-224.
114. Verkleij-Hagoort A., Verlinde M., Ursem N.T.C., et al. Maternal hyperhomocysteinemia is a risk factor for congenital heart disease. BJOG 2006, 113:1412-1418.
115. Solanky N., Jimenez A.R., D'Souza S.W., Sibley C.P., Glazier J.D. Expression of folate transporters in human placenta and implications for homocysteine metabolism. Placenta 2010, 31:131-143.
116. Tsitsiou E., Sibley C.P., D'Souza S.W., Catanescu O., Jacobsen D.W., Glazier J.D. Homocysteine transport by systems L, A and y+L across the microvillous plasma membrane of human placenta. J. Physiol. 2009, 587(Pt. 16):4001-4013.
117. Malinow M.R., Rajkovic A., Duell P.B., Hess D.L., Upson B.M. The relationship between maternal and neonatal umbilical cord plasma homocyst(e)ine suggests a potential role for maternal homocyst(e)ine in fetal metabolism. Am. J. Obstet. Gynecol. 1998, 178:228-233.
118. Molloy A.M., Mills J.L., McPartlin J., Kirke P.N., Scott J.M., Daly S. Maternal and fetal plasma homocysteine concentrations at birth: the influence of folate, vitamin B12, and the 5,10-methylenetetrahydrofolate reductase 677C->T variant. Am. J. Obstet. Gynecol. 2002, 186:499-503.
119. Roberts J.M., Pearson G.D., Cutler J.A., Lindheimer M.D. Summary of the NHLBI working group on research on hypertension during pregnancy. Hypertens. Pregnancy 2003, 22:109-127.
120. Hawfield A., Freedman B.I. Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection. Ther. Adv. Cardiovasc. Dis. 2009, 3:65-74.
121. Sorensen T.K., Malinow M.R., Williams M.A., King I.B., Luthy D.A. Elevated second-trimester serum homocyst(e)ine levels and subsequent risk of preeclampsia. Gynecol. Obstet. Invest. 1999, 48:98-103.
122. Hietala R., Turpeinen U., Laatikainen T. Serum homocysteine at 16 weeks and subsequent preeclampsia. Obstet. Gynecol. 2001, 97:527-529.
123. Rajkovic A., Catalano P.M., Malinow M.R. Elevated homocyst(e)ine levels with preeclampsia. Obstet. Gynecol. 1997, 90:168-171.
124. Powers R.W., Evans R.W., Majors A.K., et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am. J. Obstet. Gynecol. 1998, 179:1605-1611.
125. Hogg B.B., Tamura T., Johnston K.E., Dubard M.B., Goldenberg R.L. Second-trimester plasma homocysteine levels and pregnancy-induced hypertension, preeclampsia, and intrauterine growth restriction. Am. J. Obstet. Gynecol. 2000, 183:805-809.
126. Gurbuz A., Karateke A., Mengulluoglu M. Elevated plasma homocysteine levels in preeclampsia and eclampsia. Int. J. Gynaecol. Obstet. 2004, 87:165-166.
127. Braekke K., Ueland P.M., Harsem N.K., Karlsen A., Blomhoff R., Staff A.C. Homocysteine, cysteine, and related metabolites in maternal and fetal plasma in preeclampsia. Pediatr. Res. 2007, 62:319-324.
128. Mao D., Che J., Li K., et al. Association of homocysteine, asymmetric dimethylarginine, and nitric oxide with preeclampsia. Arch. Gynecol. Obstet. 2010, 282:371-375. ; PMID: 19806356.
129. Yu C.K., Lakasing L., Papageorghiou A.T., Spencer K., Nicolaides K.H. Uterine artery Doppler and mid-trimester maternal plasma homocysteine in subsequent pre-eclampsia. J. Matern. Fetal Neonatal Med. 2004, 16:134-139.
130. Kahn S.R., Platt R., McNamara H., et al. Inherited thrombophilia and preeclampsia within a multicenter cohort: the Montreal preeclampsia study. Am. J. Obstet. Gynecol. 2009, 200:151.e1-151.e9.
131. Refsum H., Smith A.D., Ueland P.M., et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin. Chem. 2004, 50:3-32.
132. Vollset S.E., Refsum H., Irgens L.M., et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am. J. Clin. Nutr. 2000, 71:962-968.
133. Infante-Rivard C., Rivard G.E., Gauthier R., Théorêt Y. Unexpected relationship between plasma homocysteine and intrauterine growth restriction. Clin. Chem. 2003, 49:1476-1482.
134. Grandone E., Colaizzo D., Vecchione G. Homocysteine levels in amniotic fluid. Thromb. Haemost. 2006, 95:625-628.
135. Bar-Or D., Heybourne K.D., Bar-Or R., Rael L.T., Winkler J.V., Navot D. Cysteinylation of maternal plasma albumin and its association with intrauterine growth restriction. Prenat. Diagn. 2005, 25:245-249.
136. Tarim E., Bagis T., Kilicdag E., et al. Elevated plasma homocysteine levels in gestational diabetes mellitus. Acta Obstet. Gynecol. Scand. 2004, 83:543-547.
137. Seghieri G., Breschi M.C., Anichini R., et al. Serum homocysteine levels are increased in women with gestational diabetes mellitus. Metabolism 2003, 52:720-723.
138. Guven M.A., Kilinc M., Batukan C., Ekerbicer H.C., Aksu T. Elevated second trimester serum homocysteine levels in women with gestational diabetes mellitus. Arch. Gynecol. Obstet. 2006, 274:333-337.
139. López-Quesada E., Vilaseca M.A., Gómez E., Lailla J.M. Are plasma total homocysteine and other amino acids associated with glucose intolerance in uncomplicated pregnancies and preeclampsia?. Eur. J. Obstet. Gynecol. 2005, 119:36-41.
140. Knudtson E.J., Smith K., Mercer B.M., et al. Serum homocysteine levels after preterm premature rupture of the membranes. Am. J. Obstet. Gynecol. 2004, 191:537-541.
141. Ferguson S.E., Smith G.N., Salenieks M.E., Windrim R., Walker M.C. Preterm premature rupture of membranes, nutritional and socioeconomic factors. Obstet. Gynecol. 2002, 100:1250-1256.
142. Owen E.P., Human L., Carolissen A.A., Harley E.H., Odendaal H.J. Hyperhomocysteinemia-a risk factor for abruptio placentae. J. Inherit. Metab. Dis. 1997, 20:359-362.
143. Van der Molen E.F., Verbruggen B., Nováková I., Eskes T.K.A.B., Monnens L.A.H., Blom H.J. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. Br. J. Obstet. Gynecol. 2000, 107:785-791.
144. Ananth C.V., Elsasser D.A., Kinzler W.L., et al. Polymorphisms in methionine synthase reductase and betaine-homocysteine S-methyltransferase genes: risk of placental abruption. Mol. Genet. Metab. 2007, 91:104-110.
145. Kramer M.S., Kahn S.R., Rozen R., et al. Vasculopathic and thrombophilic risk factors for spontaneous preterm birth. Int. J. Epidemiol. 2009, 38:715-723.
146. O'Leary V.B., Parle-McDermott A., Molloy A.M., et al. MTRR and MTHFR polymorphism: link to Down syndrome?. Am. J. Med. Genet. 2002, 107:151-155.
147. Coopede F. The complex relationship between folate/homocysteine metabolism and risk of Down syndrome. Mutat. Res. 2009, 682:54-70.
148. Fryer A.A., Nafee T.M., Ismail K.M.K., Carroll W.D., Emes R.D., Farrell W.E. LINE-1 DNA methylation is inversely correlated with cord plasma homocysteine in man. A preliminary study. Epigenetics 2009, 4:394-398.
149. Barker D.J., Gluckman P.D., Godfrey K.M., Harding J.E., Owens J.A., Robinson J.S. Fetal nutrition and cardiovascular disease in adult life. Lancet 1993, 341:938-941.
150. Picker J.D., Coyle J.T. Do maternal folate and homocysteine levels play a role in neurodevelopmental processes that increase the risk of schizophrenia?. Harv. Rev. Psychiatry 2005, 13:197-205.
151. Lipton S.A., Kim W.K., Choi Y.B., et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor. Proc. Natl. Acad. Sci. USA 1997, 94:5923-5928.
152. Fuchs S.A., de Sain-van der Velden M.G.M., de Barse M.M.J., et al. Two mass-spectrometric techniques for quantifying serine enantiomers and glycine in cerebrospinal fluid: potential confounders and age-dependent ranges. Clin. Chem. 2008, 54:1443-1450.
153. Palmer A.M., Marion D.W., Botscheller M.L., Bowen D.M., DeKosky S.T. Increased transmitter amino acid concentration in human ventricular CSF after brain trauma. NeuroReport 1994, 6:153-156.
154. Castillo J., Dávalos A., Naveiro J., Noya M. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke 1996, 27:1060-1065.
155. Wang C., Mcinnis J., Ross-Sanchez M., Shinnick-Gallagher P., Wiley J.L., Johnson K.M. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 2001, 107:535-550.